RxDoctor Payments Data

William Butz, MD

Family Medicine · Red Oak, IANPI 1649384868

Payments from drug & device makers

$1,536in general payments, 2019–2025

Across 107 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$305
  • Novo Nordisk$287
  • AstraZeneca$198
  • AbbVie$181
  • Boehringer Ingelheim$115
  • Sanofi-aventis U.S. LLC$94
  • plus $356 from 11 others

What the payments were for

  • Food & beverage$1,530100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,536 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$1,569
Medicare patients
34
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$73,206
EliquisApixaban95$56,355
JardianceEmpagliflozin59$54,198
TrulicityDulaglutide23$29,090
EntrestoSacubitril/Valsartan22$24,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,294
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog68$23,105
XareltoRivaroxaban40$18,569
RybelsusSemaglutide17$16,070
LinzessLinaclotide15$12,521
MyrbetriqMirabegron14$9,530
Bevespi AerosphereGlycopyrrolate/Formoterol Fum20$8,452
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,335
Tresiba Flextouch U-100Insulin Degludec12$5,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$287$89,27692 claims
Boehringer IngelheimJardiance, Stiolto Respimat$115$61,53271 claims
PfizerEliquis, Dilantin$305$57,543121 claims
GSKTrelegy Ellipta$40$23,29430 claims
Johnson & JohnsonXarelto$48$18,56940 claims
AbbVieLinzess$181$12,52115 claims
AstraZenecaBevespi Aerosphere, Symbicort$198$11,89734 claims
Astellas Pharma US IncMyrbetriq$87$9,53014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Red Oak

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →